|
|
 |
|
Viewing report
|
|
|
|
Pipeline Insight: Antipsychotics - Novel Antipsychotics Driving Market Evolution
Datamonitor, Nov 2003, Pages: 166
Introduction
The antipsychotic market is worth an estimated $10.7 billion and is led by Eli Lilly’s blockbuster Zyprexa. After 2007, the market is expected to plateau due to the genericization of Janssen’s Risperdal and Pfizer’s Geodon. However, Bristol-Myers Squibb’s dopaminergic modulator Abilify, launched in 2002. has acheived good uptake and is predicted to reach blockbuster status by 2009.
Scope
Detailed coverage of the patient potential, unmet needs, and clinical trial design of antipsychotics across the seven major markets
Overview of drugs in preregistration, Phase III, II, I and preclinical development, with in-depth profiles of Organon and Sanofi-Synthelabo
Profiles of compounds undergoing development for schizophrenia, with sales forecasts to 2011
Insight into current research for novel diagnostic tests and the genetic basis of psychosis
Report Highlights
The current late stage antipsychotic pipeline is unlikely to yield a blockbuster product over the forecast period. Novartis has discontinued research of Zomaril with the drug now available for out-licensing, leaving Novartis’ antipsychotic pipeline empty.
Lundbeck’s Serdolect is set for relaunch in 2005, with post-marketing studies demonstrating that the drugs efficacy and safety profile is comparable to current frontline antipsychotics. However, Datamonitor is unsure whether this is enough to dispel the negative association with heart problems.
Novel neurotransmitter receptor ligands form the majority of drugs in Phase II and below. Due to the predicted high specificity and narrowed spectrum of efficacy, Datamonitor believes these compounds will be investigated as adjuncts, as a precursor to the predicted future of polytherapy.
Reasons to Purchase
Understand unmet needs in the antipsychotics market to identify new opportunities
Assess the commercial potential of new products entering the market
Identify in-licensing and co-promotional opportunities
Customers who bought this item also bought
Drugs of Tomorrow 2001: Antipsychotics - New Players in an Expanding Market
Br. Holdings Corporation
Br Malls Participacoes Sa
Drugs of Tomorrow: Antipsychotics - Gaining Competitive Advantage From a Limited Research Base
Market Dynamics: Antipsychotics - A Market Driven by Reformulation
Drugs of Tomorrow 2002: Depression - A pipeline driven by side effect profile
Chinese Markets for Polybutadiene Rubber (BR)
Commercial Insight: Antipsychotics - From Blockbuster Brands to Billion Dollar Generics
Stakeholder Insight: Inflammatory Bowel Disease - Efficacy and Compliance Key to Maximizing Patient Share as Novel Biologics Wait in the Wings
Drugs of Tomorrow 2001: Stable Angina - An Unsatisfactory R&D Pipeline Facing Chronic Unmet Needs
Drugs of Tomorrow 2001: Diabetes
Pipeline Insight: Depression - Novel therapies key to market penetration
|
|
|
|
